Form 4: Lexeo Therapeutics CFO Kyle Rasbach Reports Stock and Option Awards
SEC Form 4 Filing
Chief Financial Officer Kyle Rasbach of Lexeo Therapeutics reports the acquisition of restricted stock units and stock options.
Summary
- On January 17, 2025, Kyle Rasbach, the Chief Financial Officer of Lexeo Therapeutics, reported the acquisition of 40,875 restricted stock units (RSUs) and stock options for 245,250 shares.
- The RSUs were granted at a price of $0.
- 25% of the RSUs vest on February 15, 2026, with the remainder vesting quarterly thereafter, contingent upon continued service.
- Stock options are exercisable at $5.07 per share.
- 25% of the shares underlying the option vest on December 18, 2025, and the remainder vest monthly thereafter, contingent upon continued service.
- The options expire on January 16, 2035.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, indicating stability and alignment of interests. It's a neutral to slightly positive signal.
Positives
- The grant of RSUs and stock options to the CFO aligns his interests with those of the shareholders.
- The vesting schedules incentivize continued service and commitment to the company's long-term success.
Future Outlook
The vesting schedules for the RSUs and stock options suggest an expectation of continued service and contribution from the CFO.
Industry Context
Stock option and RSU grants are common compensation practices in the biotech industry to attract and retain key executives.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
- Vesting schedules are typical, designed to incentivize long-term commitment.
- The specific amounts and terms would need to be compared to peer companies of similar size and stage of development to assess competitiveness.
Stakeholder Impact
- Shareholders may view the grants as aligning management's interests with the company's long-term performance.
- Employees may see this as a positive sign of investment in leadership.
Key Dates
| Date | Description |
|---|---|
| 01/17/2025 | Date of transaction: acquisition of RSUs and stock options |
| 01/22/2025 | Date of Form 4 filing |
| 02/15/2026 | Initial vesting date for 25% of RSUs |
| 12/18/2025 | Initial vesting date for 25% of stock options |
| 01/16/2035 | Expiration date for stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.